E. Irajizad

A blood-based metabolic signature for earlier detection of lung cancer.

Metabolomic profiling was applied to 1,259 sera collected within five years of a lung cancer diagnosis and 8,470 non-case sera from ever-smoker participants in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial to identify metabolic signatures for the earlier detection of lung cancer. We develop...

Assessment of impending pancreatic cancer in a cohort of new onset diabetes on basis of biomarker trajectory

Multi-Objective Composite Longitudinal Biomarker Scores for Improved Cancer Risk Assessment

Improved Parametric Empirical Bayes (iPEB), which accounts for the intervals between serial measurements, adjusts for covariates, and performs feature selection and optimized biomarker combination, improved lung cancer risk assessment in independent PLCO data, supporting objective-driven optimization of longitudinal bi...

A blood-based signature of cytoskeletal and extracellular remodeling for risk stratification of intraductal papillary mucinous neoplasms

Integrated proteomic and spatial transcriptomic datasets of IPMN tissues revealed coordinated alterations cytoskeletal and ECM remodeling and elevated matrix stiffness as prominent features associated with IPMN/PDAC, which paralleled concordant increases in BGN and ITGB1BP1.